Corporate overview
Founded in 2001, TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications.
TaiGen has built a fully-integrated pharmaceutical company by pursuing a business strategy that capitalizes on the management team's extensive expertise in drug discovery, development, global regulatory approval processes, and commercialization in China. Senior executives at TaiGen were recruited from both major pharmaceutical/biotech companies in the West as well as from Asian-based multinational companies. This unique expertise allows the company to focus on in-licensing late-stage innovative drugs targeting Asian-prevalent diseases to complement its own internal research programs as well as to partner its organic drug development programs. In addition, TaiGen has formed marketing alliances to capture the rapidly-expanding Asian pharmaceutical market.
TaiGen is headquartered in Taipei, Taiwan with 91 FTEs including 70 R&D staff at a state-of-the-art research facility of 50,000 square feet. The company has a wholly-owned Beijing subsidiary with a proven capacity to conduct clinical trials and complete 'First Class New Drug' registration (NCE not yet approved for marketing in any country).
TaiGen's current pipeline includes "first-in-class" and "best-in-class" products from pre-clinical to Phase II development, with worldwide IP rights.
Corporate financing
TaiGen is considered one of the leading biotech companies in Asia, in terms of new drug R&D capacity and financing. The company has held three rounds of financing attracting a total of US$114 mil. The first round was led by MPM Capital, one of the leading US biotech venture funds. The second-round was led by China Steel. In January, 2009, US$39 mil. was raised through the private placement of preferred C stock.
Investors in TaiGen include the National Development Fund, YFY Group, China Development Industrial Bank, Shin Kong Life Insurance, Taiwan Sugar Corporation, Yao-Hwa Glass Management Commission, Fujisawa Pharmaceuticals, and Taiwan Global BioFund. The Taiwan government, through its biotech development initiatives, has provided a US$5 mil. grant to TaiGen for assistance in its preclinical and clinical development programs.
|
